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a b s t r a c t 
We describe the case of a 65-year-old female with a history of left-sided ductal carcinoma in 
situ in 2008. Mammography in January 2020 demonstrated calcifications in the previously 
affected breast. Subsequent stereotactic biopsy results were benign. In the months that fol- 
lowed, the patient experienced breast changes but avoided returning to the facility as the 
COVID-19 pandemic worsened. In August of 2020, the patient returned for a repeat mam- 
mogram, which indicated 2 suspicious masses in the left breast. Further analysis through 
ultrasound-guided core biopsy ultimately led to a left mastectomy and lymph node biopsy, 
which were performed in September 2020. Pathology results revealed multifocal invasive 
ductal carcinoma stage IIB. 
© 2021 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Case report 
A 65-year-old female presented in January 2020 for routine 
screening mammography. She had a history of ductal carci- 
noma in situ (DCIS) of the left breast in 2008, treated with 
lumpectomy, radiation, and a 4-year course of Tamoxifen. The 
Tamoxifen treatment was intended to reduce the risk of recur- 
rence, however it was halted prematurely due to the patient’s 
intolerance of the side effects. Medical records state that her 
DCIS was estrogen receptor-positive (ER + ) and progesterone 
receptor-negative (PR-). The grade is unknown; however, the 
inclusion of radiation in her treatment plan indicates it was 
likely high-grade. After her initial diagnosis, the patient un- 
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derwent annual mammography, which showed longitudinal 
stability of postoperative changes and tissue density. No addi- 
tional relevant medical history was noted. Since the patient is 
adopted, no family history is available. 
Her mammogram revealed new coarse heterogeneous cal- 
cifications 7 cm from the nipple in the inferomedial quadrant 
of the left breast ( Fig. 1 A-B). The postlumpectomy changes of 
the breast were stable at this time. These findings were as- 
sessed as BI-RADS category 4B: Moderate suspicion for ma- 
lignancy. Supplemental screening ultrasound was not offered, 
as it is not available at the facility and is not required in the 
state. A stereotactic biopsy was performed later that month 
and indicated proliferative fibrocystic changes, fibroadenoma- 
toid hyperplasia, and benign calcifications. The patient was 
https://doi.org/10.1016/j.radcr.2021.04.003 
1930-0433/© 2021 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the 
CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Fig. 1 – A-B: CC and MLO diagnostic mammography views 
from January 2020 demonstrate coarse heterogeneous 
calcifications in the lower inner quadrant, 7 cm from the 
nipple (arrow). BIRADS 4B – stereotactic core biopsy 
recommended. 
scheduled to return for a repeat mammogram in 6 months 
based upon the benign pathology result. 
In May 2020, the patient noticed shrinking and hardening 
of the left breast. Concerned about the ongoing COVID-19 pan- 
demic, the patient chose not to return to the medical facility 
for reevaluation and instead attributed these breast changes 
to complications stemming from the stereotactic biopsy per- 
formed in January. 
The patient returned in August 2020 for a 6-month follow- 
up mammogram which demonstrated new architectural 
distortion measuring 15 mm in diameter, at 1:00 in the su- 
peromedial quadrant of the left breast 4 cm from the nipple 
( Fig. 2 A-B), distant from the site of the biopsy performed in 
January. A breast ultrasound indicated an irregular, shadowing 
mass with angular and spiculated margins (3.1 × 1.1 × 3 cm) 
correlating to the area of architectural distortion identified 
by mammography ( Fig. 3 A-B). This scan also demonstrated 
an additional 1.5 × 1.5 × 0.9 cm oval, irregular mass with 
angular margins in the same breast quadrant, at 3:00 3 cm 
from the nipple ( Fig. 4 ). The 3 axillary lymph nodes identified 
on ultrasound had a benign appearance. 
An ultrasound-guided core biopsy was performed on the 
2 masses identified. Both masses were interpreted as inva- 
sive ductal carcinoma (IDC) grade 2. Immunohistochemistry 
revealed that both tumors were ER + 95%, PR-, and HER 2 
Fig. 2 – A-B: Follow-up CC and MLO diagnostic 
mammography views from August 2020 revealed a 15 mm 
area of architectural distortion at 1:00 4 cm from the nipple 
(star). Additionally, the area of architectural distortion is 
much denser as compared to the similar area on the 
January 2020 exam. Finally, the breast has decreased in 
size relative to the prior exam. 
oncogene-negative (Her2-). As the larger mass fell between 20 
and 50 mm, the primary tumor was classified as T2. 
The patient underwent a left mastectomy with biopsies of 
4 sentinel lymph nodes in September 2020. In the absence 
of symptoms of advanced metastasis (Mo), more comprehen- 
sive imaging studies were not performed in congruence with 
the guidelines of the National Comprehensive Cancer Clinic 
[1] . Micrometastasis was observed in 1 of the 4 lymph nodes 
(N1mi). Biopsy pathology and the biomarker results confirmed 
a diagnosis of multifocal IDC stage IIB (pT2mN1miMo). Ad- 
juvant chemotherapy was initiated (TC—docetaxel with cy- 
clophosphamide). An aromatase inhibitor was also prescribed 
for adjuvant endocrine therapy. 
Discussion 
DCIS occurs when malignant epithelial cells spread within 
the mammary ducts. Proliferation beyond the ducts results in 
IDC. While the incidence of DCIS increased with the advent 
of screening to make up 32.5 per 100,000 women in 2004, IDC 
maintained a higher incidence of 124.3 per 100,000 women [2] . 
One-in-ten women treated for DCIS will later develop recur- 
rent DCIS or IDC in the same breast, as occurred in the patient 
profiled in this case study [3] . DCIS grade can predict future 
IDC. In 2 cohorts of DCIS patients, the low-grade group had a 
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Fig. 3 – A-B: Radial and antiradial ultrasound images in 
August 2020 demonstrate an irregular, shadowing mass 
(star) with angular and subtle, spiculated margins at 1:00 4 
cm from the nipple measuring 3.1 × 1.1 × 3.3 cm. This 
correlated with the mammographic finding, was given a 
BI-RADS 5 assessment, and ultimately underwent 
ultrasound-guided core biopsy. 
12-year invasive local recurrence rate of 7.5% while the high- 
grade group had a rate of 13.4% [4] . 
While DCIS and IDC may be first detected by screening, 
IDC may also present with appreciable breast changes. These 
include thickened, dimpled, or reddened breast skin, nipple 
discharge or pain, and palpable lumps in the breast or axilla 
[5] . Multifocal IDC is traditionally defined as separate tumors 
within a breast quadrant, while multicentric IDC typically 
refers to tumors separated by normal tissue and unconfined 
to a single quadrant. As many studies do not distinguish 
between the 2, the incidence of multifocal IDC appears to 
range from 6% to 60% [6] . 
Following imaging, biomarker analysis, and biopsy pathol- 
ogy, surgical removal of the IDC tissue may proceed. In mul- 
tifocal IDC, the noncancerous tissue from the affected breast 
has a higher likelihood of being able to be conserved [7] . Do- 
cetaxel and cyclophosphamide (TC) are the standard adju- 
vant therapy for early-stage, HER- IDC [8] . Patients additionally 
prescribed aromatase inhibitors have demonstrated approxi- 
mately 40% lower breast cancer 10-year mortality rates than 
those not treated with endocrine therapy [9] . 
After a state of emergency was declared in the United 
States in March of 2020, many outpatient health care facili- 
ties closed to divert resources to the COVID-19 crisis . Individ- 
uals postponed elective screening due to concerns about the 
virus. Screening mammography rates dropped by as much as 
Fig 4 – Also in August 2020, an additional oval, irregular 
mass with angular margins (star) was noted at 3:00 3 cm 
from the nipple measuring 1.5 × 0.9 × 0.9 cm. This was 
also given a BI-RADS 5 assessment and ultrasound-guided 
core biopsy was performed. 
94% [10] . Initially, COVID-19 infection was suspected to impact 
cancer patients more severely. As the pandemic has contin- 
ued, international studies such as the COVID-19 and Cancer 
Consortium have demonstrated that cancer patients and in- 
dividuals without cancer share a similar risk of complications 
or death from COVID-19. This was true regardless of cancer 
type, treatment type, and treatment timing [11] . 
This patient’s case illustrates that those with increased 
risk of breast cancer or those who are symptomatic should 
not delay further evaluation, as disease can progress relatively 
quickly. In this instance, the patient’s findings of a hardened, 
shrinking breast were a cause for concern for the devel- 
opment of an underlying malignancy. Unfortunately, these 
findings were misinterpreted as a complication of the recent 
benign biopsy. This case also highlights the rapidity with 
which breast malignancy may manifest. The initial benign 
biopsy was for calcifications in a distant area of the breast 
from which the cancer became evident within 6 months. 
Despite the pandemic, patients with worrisome self-reported 
physical exam findings should seek clinical evaluation by a 
healthcare provider. 
Patient consent 
Written, informed consent was obtained from the patient fea- 
tured in this case report. 
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